FGFR2 and cholangiocarcinoma: For example, infigratinib was granted an accelerated approval in May 2021 for advanced cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) alterations based on a single-arm study showing ORR of 23%.11